Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 3.05B | 2.96B | 2.96B | 2.97B | 2.79B | 2.37B |
Gross Profit | 1.80B | 1.76B | 1.76B | 1.72B | 1.63B | 1.36B |
EBITDA | 1.06B | 1.04B | 1.00B | 1.02B | 982.81M | 785.35M |
Net Income | 661.39M | 637.83M | 642.23M | 707.75M | 692.84M | 521.57M |
Balance Sheet | ||||||
Total Assets | 4.72B | 4.55B | 4.63B | 3.28B | 3.09B | 2.84B |
Cash, Cash Equivalents and Short-Term Investments | 367.21M | 325.36M | 395.97M | 481.39M | 569.28M | 443.15M |
Total Debt | 1.54B | 1.70B | 2.44B | 1.66B | 1.60B | 1.45B |
Total Liabilities | 2.56B | 2.73B | 3.48B | 2.78B | 2.73B | 2.61B |
Stockholders Equity | 2.16B | 1.83B | 1.15B | 504.49M | 367.55M | 232.14M |
Cash Flow | ||||||
Free Cash Flow | 619.36M | 619.64M | 442.18M | 428.20M | 579.01M | 618.12M |
Operating Cash Flow | 745.41M | 762.12M | 602.81M | 611.66M | 747.27M | 790.51M |
Investing Cash Flow | -162.76M | -144.02M | -1.44B | -107.97M | -231.63M | -264.09M |
Financing Cash Flow | -544.74M | -696.67M | 754.95M | -509.63M | -438.27M | -440.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $35.50B | 29.36 | 19.88% | 0.78% | 4.48% | -11.52% | |
78 Outperform | $186.06B | 28.22 | 13.44% | 0.34% | 2.05% | 7.03% | |
77 Outperform | $51.77B | 53.22 | 64.87% | ― | 6.68% | 18.84% | |
70 Outperform | $17.65B | 26.15 | 37.03% | ― | 5.89% | 10.61% | |
69 Neutral | $147.38B | 43.28 | 6.68% | 0.59% | -3.24% | -16.60% | |
69 Neutral | $26.80B | 32.32 | -680.23% | ― | 3.11% | 8.50% | |
51 Neutral | $7.90B | -0.33 | -41.69% | 2.23% | 23.45% | -1.99% |
On July 13, 2025, Waters Corporation announced a definitive agreement with Becton, Dickinson and Company (BD) and its subsidiary SpinCo for a Reverse Morris Trust transaction. This strategic move involves the reorganization and spin-off of BD’s Biosciences and Diagnostic Solutions business, followed by a merger with Waters, making SpinCo a wholly-owned subsidiary of Waters. The transaction, unanimously approved by both companies’ boards, will result in Waters shareholders owning approximately 60.8% and former SpinCo shareholders owning about 39.2% of Waters’ common stock. This merger is expected to enhance Waters’ industry positioning by expanding its capabilities in the biosciences sector.
On July 14, 2025, Waters Corporation announced a definitive agreement to merge with BD’s Biosciences and Diagnostics Solutions business, creating a life science and diagnostics leader. The transaction, valued at approximately $17.5 billion, is expected to double Waters’ total addressable market to $40 billion and generate significant synergies, including $345 million in annualized EBITDA synergies by 2030. The merger aims to enhance market access, improve service support, and drive growth in high-growth adjacencies, with an anticipated pro forma revenue of $6.5 billion in 2025.
On May 22, 2025, Waters Corporation amended its existing credit agreement, removing a $200 million term loan facility while retaining a $1.8 billion senior unsecured revolving credit facility, which matures in 2030. This strategic financial restructuring allows Waters Corporation to maintain flexibility for general corporate purposes, including debt repayment and acquisitions, and positions the company to manage its leverage ratio effectively, ensuring compliance with financial covenants and enhancing its operational capabilities.